# Study of Inhaled DMC-IH1 and Intramuscular (EpiPen®) Epinephrine in Healthy Male and Female Participants.

> **NCT06013150** · PHASE1 · COMPLETED · sponsor: **De Motu Cordis** · enrollment: 24 (actual)

## Conditions studied

- Anaphylactic Reaction

## Interventions

- **DRUG:** Epinephrine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06013150
- **Lead sponsor:** De Motu Cordis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-24
- **Primary completion:** 2023-12-15
- **Final completion:** 2024-07-10
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2024-08-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06013150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06013150, "Study of Inhaled DMC-IH1 and Intramuscular (EpiPen®) Epinephrine in Healthy Male and Female Participants.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06013150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*